文献速递临床试验与 GCP

右美托咪定对胃和食管内镜黏膜下剥离术患者术后疼痛的疗效:一项随机对照前瞻性试验的研究方案

Efficacy of dexmedetomidine on postoperative pain in patients undergoing gastric and esophageal endoscopic submucosal dissection: a study protocol for a randomized controlled prospective trial.
PubMed 文献 · Trials · 2022-06-13

本研究为前瞻性、单中心、双臂随机对照试验,拟纳入120例接受胃或食管内镜黏膜下剥离术(ESD)的患者,按手术类型分层后随机分为右美托咪定(DEX)组(n=60)与对照组(n=60),比较术后48小时内视觉模拟量表(VAS)评分等指标,以探讨术中应用DEX对术后疼痛的疗效。

要点

  • ESD术后中重度疼痛发生率可高达44.9~62.8%,目前对ESD术后镇痛方案尚无统一认识。
  • DEX组给予负荷剂量1 μg/kg持续15分钟,继以0.6 μg/kg/h持续输注至术毕前30分钟。
  • 主要结局为ESD术后2小时的VAS评分,次要结局包括多个时点VAS及围术期指标。

核心结论

  • 本研究结果将展示术中应用DEX对接受ESD患者的术后疼痛治疗有益。
  • 本研究不仅将证实ESD患者术后疼痛治疗是必要的,还为术后镇痛提供一种有效的麻醉方法。

研究设计与样本

  • 本研究为前瞻性、单中心、双臂随机对照试验,共纳入120例接受内镜黏膜下剥离术的患者。
  • 患者按手术类型(胃ESD或食管ESD)分层后随机分为DEX组(D组,n=60)和对照组(C组,n=60)。
  • DEX组给予负荷剂量DEX 1 μg/kg持续15分钟,继以0.6 μg/kg/h持续输注至术毕前30分钟;对照组输注等量生理盐水。

主要发现

  • 主要结局为ESD术后2小时的VAS评分。
  • 次要结局为术后1小时、4小时、6小时、18小时、24小时和48小时的VAS评分,围术期血流动力学状态,补救镇痛药使用,镇静评分,寒战,术后恶心呕吐(PONV),患者满意度评分及ESD并发症(如出血、穿孔、吸入性肺炎)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endoscopic submucosal dissection (ESD) is widely used as an effective treatment of early gastric and esophageal tumors, as it is minimally invasive, safe, and convenient. Epigastric pain is a common complication of ESD. In the traditional cognition, the postoperative pain of ESD is not serious and does not attach too much attention. However, previous studies found that the incidence of moderate to severe pain after ESD can be as high as 44.9~62.8%. At present, there is no unified understanding of how to carry out good postoperative analgesia in patients undergoing ESD of stomach and esophagus. The purpose of present study is to investigate the efficacy of intraoperative dexmedetomidine (DEX) using on postoperative pain though observing the postoperative visual analog scale (VAS) score within 48 h after ESD surgery, so as to explore an effective analgesia and anesthetic method in patients undergoing gastric and esophagus ESD. METHODS/DESIGN: This study is a prospective, single-center, two-arm, randomized control trail. In total, 120 patients undergoing endoscopic submucosal dissection were stratified by type of surgery (i.e., gastric or esophagus ESD) and randomized into two treatment groups, DEX group (group D, n = 60) and control group (group C, n = 60). Patients in the experimental group (DEX group) will be administrated a loading dose of DEX at 1 μg/kg for 15 min and a continuous infusion at 0.6 μg/kg/h until 30 min before the end of operation. In control group, the same volume of normal saline was infused. The primary outcome is VAS at 2 h after ESD surgery. The secondary outcome will be VAS at 1 h, 4 h, 6 h,18 h, 24 h, and 48 h, the status of perioperative hemodynamics, the use of remedial analgesics, sedation score, shivering, postoperative nausea and vomiting (PONV), and satisfaction scores of patient and complication of ESD (such as bleeding, perforation, aspiration pneumonia). DISCUSSION: The results of this study will demonstrate that intraoperative application of DEX is beneficial for postoperative pain treatment in patients undergoing ESD. This study will not only confirm that postoperative pain treatment is necessary for patients undergoing ESD but also provides an effective anesthesia method for postoperative analgesia. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ID: ChiCTR2100043837 , registered on March 4, 2021, http://www.chictr.org.cn .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Luo X, An LX, Chen PS, et al. Efficacy of dexmedetomidine on postoperative pain in patients undergoing gastric and esophageal endoscopic submucosal dissection: a study protocol for a randomized controlled prospective trial. Trials. 2022. PMID: 35698203. doi:10.1186/s13063-022-06432-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。